Article Text

Download PDFPDF
The Long-Term Efficacy of Neoadjuvant Chemotherapy Followed by Radical Hysterectomy Compared With Radical Surgery Alone or Concurrent Chemoradiotherapy on Locally Advanced-Stage Cervical Cancer
  1. Mingzhu Yin, PhD*,
  2. Falin Zhao, PhD,,
  3. Ge Lou, MD*,
  4. Haiyu Zhang, PhD,
  5. Meng Sun, PhD,
  6. Cong Li, PhD§,
  7. Yan Hou, PhD,
  8. Xia Li, PhD,
  9. Fanling Meng, MD* and
  10. Xiuwei Chen, MD*
  1. * Department of Gynecology, The Third Affiliated Hospital of Harbin Medical University;
  2. College of Medicine and Health Management, Hangzhou Normal University, Hangzhou, Zhejiang Province;
  3. Department of Biostatistics, Harbin Medical University;
  4. § Department of Pathology, The Affiliated Tumor Hospital of Harbin Medical University; and
  5. Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  1. Address correspondence and reprint requests to Ge Lou, MD, Department of Gynecology, The Affiliated, Tumor Hospital, Harbin Medical University, Harbin 150081, China. E-mail: doctorlouge{at}


Objectives: The purpose of this study was to compare the long-term survival of patients with locally advanced cervical cancer (stages IB2-IIB) treated with neoadjuvant chemotherapy followed by radical hysterectomy (hysterectomy plus pelvic lymph node dissection) (NACT + RS) with the survival of those treated with radical surgery (hysterectomy plus pelvic lymph node dissection) (RS) or concurrent chemoradiotherapy (CCRT).

Methods: A retrospective study was performed. Patients were followed up for 54 to 114 months (median, 82.8 months). All risk factors that may have affected the disease-free survival (DFS) and overall survival (OS) were assessed.

Results: From January 2000 to December 2005, 476 eligible patients were followed up. The 5-year DFS rates of the NACT + RS, RS, and CCRT groups were 85.00%, 77.44%, and 52.94%, respectively (P < 0.0001), whereas the 5-year OS rates were 88.67%, 80.21% and 64.37%, respectively (P < 0.0001). The NACT + RS group had significantly higher survival rates than both the RS (DFS: hazard ratio = 1.870, P = 0.0031; OS: hazard ratio = 1.813, P = 0.0175) and CCRT (DFS: hazard ratio = 3.535, P < 0.0001; OS: hazard ratio = 3.157, P < 0.0001) groups, while adjusting for the pathological type, clinical stage, tumor size (initial), and age. The 5-year DFS rate for patients receiving TP (paclitaxel and cisplatin) was 90.55%, and 71.70% for patients receiving PVB (cisplatin, vincristine, and bleomycin); the 5-year OS rates were 96.75% for TP and 70.09% for PVB, respectively. Patients receiving TP had a statistically significant improvement in both 5-year DFS and OS rates (P < 0.001).

Conclusions: Neoadjuvant NACT + RS improves the long-term DFS and OS of patients with locally advanced cervical cancer stage IB2-IIB compared with RS alone and especially compared with CCRT. In the NACT + RS group, NACT with TP improves the long-term DFS and OS of patients compared with patients who had PVB chemotherapy regimen. These results may provide some useful information for clinicians to treat patients with locally advanced cervical carcinoma.

  • Cervical carcinoma
  • Neoadjuvant chemotherapy
  • Radical hysterectomy
  • Concurrent chemoradiotherapy
  • Survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.